Precision medicine is an approach that allows doctors to understand how a patient’s genetic profile may cause cancer to grow and spread, leading to a more personalized treatment strategy based on molecular characterization of a person’s tumor. However, precision medicine as a genomics-based approach does not yet apply to all patients because genetic mutations do not always lead to changes of the corresponding proteins. Therefore, integrating genomics and proteomics data, or proteogenomics, presents as a new approach that may help make precision medicine a more effective treatment option for patients.
In the latest publication of the journal Cell, Dr. Henry Rodriguez, Director of the Office of Cancer Clinical Proteomics Research, details the evolution of precision medicine, and how the National Cancer Institute is taking key strides to coordinate with the international cancer research community to provide an integrated, open-data approach to precision oncology. These efforts allow researchers to work together and streamline research efforts, troubleshoot issues, standardize protocols and workflows, and share progress to address the challenges and advance precision medicine efforts.